BCRX

BioCryst Pharmaceuticals Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$143.3M

Burn Rate (Qtr)

$46.1M

Company Profile

BioCryst is a late-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Rapivab (peramivir)

Influenza acute

Quarterly Sales

March 05, 2021 (Est)

Rapivab (peramivir)

Acute uncomplicated influenza to pediatric patients

Quarterly Sales

March 05, 2021 (Est)

Berotralstat (BCX7353)

Eliminate or reduce attacks in HAE patients

Quarterly Sales (Approved)

February 19, 2021 (Est)

Galidesivir (BCX4430)

COVID-19

Phase 1 (Data / Information)

Q4 2020

Recent Posts

See what the community is saying - click to see full post

BCRX - Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevent

BCRX - BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones

BCRX - MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom

BCRX - BioCryst to Report Q3 2020 Financial Results on November 5

BCRX - Journal of Allergy and Clinical Immunology Publishes Results of Berotralstat for the Prevention of HAE

Upcoming September 2020 COVID-19 Therapeutic Catalyst Event

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon